MedTrace Logo

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

NCT00580047 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2023-10-04

Study results available
· View outcomes & findings →

Summary

The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.

Conditions

  • Renal Insufficiency

Interventions

DRUG

Zoledronic Acid

4mg IV Annually

COMBINATION_PRODUCT

Calcium with vitamin D

1200 mg Calcium with 800 International Units of vitamin D

DRUG

Alendronate

70mg weekly

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Lynn Mack, MD · University of Nebraska

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-01
Primary Completion
2014-07-29
Completion
2014-07-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00580047 on ClinicalTrials.gov